Sun Pharma latest to sell COVID-19 drug favipiravir in India [Reuters]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Reuters
Sun Pharma latest to sell COVID-19 drug favipiravir in India BENGALURU (Reuters) - India’s Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world’s third worst-hit nation. Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge of 50,000-plus infections for the sixth straight day on Tuesday. Sun’s version of favipiravir, to be called FluGuard, will cost 35 rupees (47 cents) per 200 mg tablet, making it the cheapest version available. Stocks will be available from this week. Shares in Sun Pharma, one of the world’s largest generic drug manufacturers, climbed after the news and were last up 1.7% in an upbeat Mumbai market. [.BO] Favipiravir was originally developed by Japan’s Fujifilm Holdings Corp as Avigan. Once hyped as a potential COVI
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights [Yahoo! Finance]Yahoo! Finance
- Autoimmune Hepatitis Diagnosis and Treatment Market Size to Reach USD 19.15 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- Winn Awards Help Physicians Solve Healthcare Disparities [Yahoo! Finance]Yahoo! Finance
- Top Pictet Fund Manager Sees Biotech Stocks Joining AI-Euphoria [Yahoo! Finance]Yahoo! Finance
- Top Pictet Fund Manager Sees Biotech Stocks Joining AI-Euphoria [BNN Bloomberg (Canada)]BNN Bloomberg
GILD
Earnings
- 2/6/24 - Miss
GILD
Sec Filings
- 3/28/24 - Form ARS
- 3/28/24 - Form DEF
- 3/28/24 - Form DEFA14A
- GILD's page on the SEC website